AbbVie(US:ABBV) Prnewswire·2025-07-10 11:30Core Insights - AbbVie and IGI Therapeutics have entered into an exclusive licensing agreement for ISB 2001, a novel investigational asset targeting relapsed/refractory multiple myeloma [1][2] - ISB 2001 is a first-in-class trispecific T-cell engager developed using IGI's BEAT® protein platform, demonstrating promising clinical results [6][7] - The agreement includes an upfront payment of $700 million to IGI, with potential milestone payments totaling up to $1.225 billion, along with tiered royalties on net sales [2] Company Overview - AbbVie is focused on discovering and delivering innovative medicines across key therapeutic areas, including oncology, with a commitment to addressing significant health issues [3][4] - The company is advancing a dynamic pipeline of investigational therapies for various cancer types, including blood cancers and solid tumors, with over 35 investigational medicines currently in clinical trials [5] Product Details - ISB 2001 targets BCMA and CD38 on myeloma cells and CD3 on T cells, currently in Phase 1 clinical trials, showing an overall response rate of 79% and a complete response rate of 30% in heavily pretreated patients [6][7] - The U.S. FDA has granted ISB 2001 Orphan Drug Designation and Fast Track Designation for treating relapsed/refractory myeloma patients [8] Technology Platform - IGI's BEAT® platform enables the development of next-generation immune cell engagers, addressing limitations of traditional bispecific antibodies and enhancing manufacturability and therapeutic potential [9]